Pilot Chemical Disinfectant Accepted for Use Against SARS-CoV-2 and More

CINCINNATI – Pilot Chemical Corp., through its subsidiary Mason Chemical Co., has secured acceptance from the Environmental Protection Agency (EPA) to add a SARS-CoV-2 claim, along with four new antimicrobial claims, to the label of its Maguard^® 5626 product.

Customers using Maguard 5626 for hard surface disinfection can now claim the product is proven effective against SARS-CoV-2, the virus that causes COVID-19, with a two-minute dwell time. Other new antimicrobial claims include: Legionella pneumophila and Candida auris for hard surface disinfection; Marek’s Disease virus as an animal premise virucide; and Vibrio cholerae for food contact surface sanitization. Customers will need to update their labels in order to make these claims.

“When it comes to fighting chemically-resistant pathogens, Maguard 5626 is a workhorse,” said Richard Rehg, Vice President of Commercial, Pilot Chemical Co. “As the pandemic continues, disinfecting and sanitizing products like this are essential in protecting our families and communities against COVID-19 and other emerging threats, and we stand united with our customers in meeting that demand.”

First launched in 2011, Maguard 5626 is an EPA-registered disinfectant that falls in the company’s disinfectant/sanitizer group of peracetic acid products and is available for supplemental registration. It offers a high level of disinfection and sanitizing capabilities. This product is used by a wide range of industries, from food protection, janitorial, oil and gas, and commercial laundry, to industrial water treatment, and pulp and paper. A highly versatile product, Maguard 5626 can be used in a broad number of environments and locations, from airports, nursing homes and healthcare facilities, to schools, office buildings, manufacturing facilities, and zoos.

Earlier this month, Maguard 5626 was among a group of Pilot products accepted by the EPA as effective against emerging viral pathogens. It is the company’s first product to gain the claim for SARS-CoV-2, and additional new claim submissions are in the pipeline, awaiting acceptance.